Tango Therapeutics, Inc. (TNGX) closed the last trading session at $9.63, gaining 22.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.22 indicates a 37.3% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $1.39. While the lowest estimate of $11.00 indicates a 14.2% increase from the current price level, the most optimistic ...

Core Viewpoint - AvePoint, Inc. (AVPT) shows significant upside potential with a mean price target of $20, indicating a 49.3% increase from the current price of $13.4 [1] Price Targets and Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $4.07, suggesting variability in analyst predictions [2] - The lowest estimate is $16.00, indicating a 19.4% increase, while the highest estimate is $28.00, suggesting a 109% increase [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about AVPT's earnings, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 115.4%, with no negative revisions [12] - AVPT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - S&P Global (SPGI) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the changing earnings picture of a company [1][2]. - Changes in earnings estimates are strongly correlated with near-term stock price movements, influenced by institutional investors who adjust their valuations based on these estimates [4]. Business Improvement Indicators - The upgrade in ratings and rising earnings estimates for S&P Global suggest an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively [5][10]. Earnings Estimate Revisions - S&P Global is projected to earn $17.71 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 3.4% over the past three months [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have generated an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places S&P Global in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Mineralys Therapeutics, Inc. (MLYS) has seen a 5.1% increase in share price over the past four weeks, closing at $38.91, with a potential upside of 27.6% based on Wall Street analysts' mean price target of $49.63 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $42.00 to a high of $56.00, with a standard deviation of $5.78, indicating variability among analysts [2] - The lowest estimate suggests a 7.9% increase from the current price, while the highest estimate indicates a 43.9% upside [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about MLYS's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, three earnings estimates have been revised upward, leading to a 6.7% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank - MLYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of MLYS's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Pagaya Technologies Ltd. (PGY) has seen a 6.4% increase in share price over the past four weeks, closing at $24.88, with analysts suggesting a potential upside of 64% based on a mean price target of $40.8 [1] Price Targets - The average price target consists of 10 estimates ranging from a low of $27.00 to a high of $54.00, with a standard deviation of $7.55, indicating variability among analysts [2] - The lowest estimate suggests an 8.5% increase from the current price, while the highest indicates a potential upside of 117% [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about PGY's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 28.1%, with one estimate moving higher and no negative revisions [12] Zacks Rank - PGY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to historical inaccuracies in predicting stock price movements [3][7][10]

Core Viewpoint - Sprinklr (CXM) shows potential for upside with a mean price target of $10.5, indicating a 32.9% increase from its current price of $7.9, following a 5.1% gain over the past four weeks [1]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $3.12, suggesting variability in analyst predictions. The lowest estimate is $8.00 (1.3% increase), while the highest is $17.00 (115.2% increase) [2]. - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about CXM's earnings prospects, with a strong consensus on revising EPS estimates higher, which correlates with potential stock price increases [11]. - The Zacks Consensus Estimate for the current year has risen by 6.8% over the past month, with two estimates increasing and no negative revisions [12]. - CXM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3]. - Price targets can often mislead investors, and while they should not be ignored, they should be approached with skepticism [10].

Profound Medical (PROF) closed the last trading session at $6.75, gaining 15.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.31 indicates an 82.4% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $2.01. While the lowest estimate of $11.00 indicates a 63% increase from the current price level, the most optimistic analyst ...

Shares of Theravance Biopharma (TBPH) have gained 25.8% over the past four weeks to close the last trading session at $18.7, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $24.43 indicates a potential upside of 30.6%.The mean estimate comprises seven short-term price targets with a standard deviation of $8.85. While the lowest estimate of $13.00 indicates a 30.5% decline from t ...

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on DXP Enterprises (DXPE), and emphasizes the importance of using these recommendations in conjunction with other research tools like the Zacks Rank to make informed investment decisions [1][5][11]. Brokerage Recommendations - DXP Enterprises has an average brokerage recommendation (ABR) of 1.83, indicating a consensus between Strong Buy and Buy, with one Strong Buy and one Buy recommendation from three brokerage firms [2][5]. - The distribution of recommendations shows that Strong Buy and Buy each account for 33.3% of the total recommendations [2]. Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the best price increase potential, often reflecting a strong positive bias due to the vested interests of brokerage firms [5][6][11]. - Analysts tend to issue more favorable ratings than their research would support, which can mislead investors [11]. Zacks Rank as an Alternative - The Zacks Rank is presented as a more reliable indicator of a stock's near-term price performance, based on earnings estimate revisions, and is classified into five groups from Strong Buy to Strong Sell [8][12]. - The Zacks Rank is updated more frequently than the ABR, making it a timely tool for predicting future stock prices [13]. Current Earnings Estimates for DXP Enterprises - The Zacks Consensus Estimate for DXP Enterprises remains unchanged at $4.75 for the current year, suggesting steady analyst views on the company's earnings prospects [14]. - The unchanged consensus estimate has resulted in a Zacks Rank of 3 (Hold) for DXP Enterprises, indicating a cautious approach despite the Buy-equivalent ABR [15].

Shares of SSR Mining (SSRM) have gained 10.1% over the past four weeks to close the last trading session at $21.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $27.23 indicates a potential upside of 27%.The mean estimate comprises 10 short-term price targets with a standard deviation of $4.63. While the lowest estimate of $18.70 indicates a 12.8% decline from the current pri ...